Cyclo Therapeutics, Inc. Analyst EPS Estimates
Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 1 | -$0.32 | -$0.08 | -$0.19 |
Q2 2024 | 1 | -$0.25 | -$0.06 | -$0.16 |
Q3 2024 | 1 | -$0.26 | -$0.06 | -$0.16 |
Q4 2024 | 2 | -$0.17 | -$0.15 | -$0.16 |
Q1 2025 | 2 | -$0.18 | -$0.07 | -$0.12 |
Q2 2025 | 1 | -$0.33 | -$0.08 | -$0.20 |
Q3 2025 | 1 | -$0.29 | -$0.07 | -$0.18 |
Q4 2025 | 1 | -$0.31 | -$0.07 | -$0.19 |
Cyclo Therapeutics, Inc. Earnings Date And Information
Cyclo Therapeutics, Inc. last posted its earnings results on Wednesday, August 14th, 2024. The company reported $-0.21 earnings per share for the quarter, missing analysts' consensus estimates of $-0.14 by $0.07. The company had revenue of 233,772 for the quarter and had revenue of 1.08 M for the year. Cyclo Therapeutics, Inc. has generated $-1 earnings per share over the last year ($-1.23 diluted earnings per share) and currently has a price-to-earnings ratio of -0.83. Cyclo Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 12th, 2024 based on prior year's report dates.
Cyclo Therapeutics, Inc. Earnings History by Quarter
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
11/13/2024 | Q3 2024 | -$0.31 | $294,000 | $233,772 | ||
08/14/2024 | Q2 2024 | -$0.14 | -$0.21 | -0.07 | $267,500 | $123,104 |
05/15/2024 | Q1 2024 | -$0.20 | -$0.15 | 0.05 | $202,450 | |
04/29/2024 | Q4 2023 | -$0.23 | $311,399 | |||
11/14/2023 | Q3 2023 | -$0.29 | $141,000 | $495,477 | ||
08/14/2023 | Q2 2023 | -$0.33 | $183,000 | $117,118 | ||
05/12/2023 | Q1 2023 | -$0.46 | $152,411 | |||
05/01/2023 | Q4 2022 | -$0.57 | $186,803 | |||
11/10/2022 | Q3 2022 | -$0.50 | $618,000 | $452,167 | ||
08/15/2022 | Q2 2022 | -$0.41 | $571,000 | $541,886 | ||
05/12/2022 | Q1 2022 | -$0.48 | $19,361.00 | 19361.48 | $194,904 | |
03/11/2022 | Q4 2021 | -$0.43 | $585,115 | |||
11/15/2021 | Q3 2021 | -$0.67 | -$0.60 | 0.07 | $382,000 | $403,918 |
08/16/2021 | Q2 2021 | -$0.56 | $360,000 | $238,590 | ||
05/14/2021 | Q1 2021 | -$0.76 | $358,133 | |||
03/12/2021 | Q4 2020 | -$0.50 | $145,586 | |||
11/12/2020 | Q3 2020 | -$0.85 | $222,462 | |||
08/14/2020 | Q2 2020 | -$1.60 | $209,594 | |||
05/15/2020 | Q1 2020 | -$2.17 | $325,734 | |||
03/30/2020 | Q4 2019 | -$1.00 | -$2.20 | -1.2 | $227,363 |
Cyclo Therapeutics, Inc. Earnings: Frequently Asked Questions
-
When is Cyclo Therapeutics, Inc.'s earnings date?
Cyclo Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 12th, 2024 based off last year's report dates.
-
How can I listen to Cyclo Therapeutics, Inc.'s earnings conference call?
The conference call for Cyclo Therapeutics, Inc.'s latest earnings report can be listened to online.
-
How can I read Cyclo Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Cyclo Therapeutics, Inc.'s latest earnings report can be read online.
-
How much revenue does Cyclo Therapeutics, Inc. generate each year?
Cyclo Therapeutics, Inc. (:CYTH) has a recorded annual revenue of $1.08 M.
-
How much profit does Cyclo Therapeutics, Inc. generate each year?
Cyclo Therapeutics, Inc. (:CYTH) has a recorded net income of $1.08 M. Cyclo Therapeutics, Inc. has generated $-1.23 earnings per share over the last four quarters.
-
What is Cyclo Therapeutics, Inc.'s price-to-earnings ratio?
Cyclo Therapeutics, Inc. (:CYTH) has a price-to-earnings ratio of -0.83 and price/earnings-to-growth ratio is 0.37.